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Abstract 
Objective: Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which gets secreted in response to nutritional 
stimuli from the gut mediating glucose-dependent insulin secretion. Interestingly, GLP-1 was recently found to be 
also increased in response to inflammatory stimuli in an interleukin 6 (IL-6) dependent manner in mice. The relevance 
of this finding to humans is unknown but has been suggested by the presence of high circulating GLP-1 levels in criti-
cally ill patients that correlated with markers of inflammation. This study was performed to elucidate, whether a direct 
link exists between inflammation and GLP-1 secretion in humans.
Research design and methods: We enrolled 22 non-diabetic patients scheduled for cardiac surgery as a reproduc-
ible inflammatory stimulus with repeated blood sampling before and after surgery.
Results: Mean total circulating GLP-1 levels significantly increased in response to surgery from 25.5 ± 15.6 pM to 
51.9 ± 42.7 pM which was not found in a control population. This was preceded by an early rise of IL6, which was 
significantly associated with GLP-1 under inflammatory but not basal conditions. Using repeated measure ANCOVA, 
IL6 best predicted the observed kinetics of GLP-1, followed by blood glucose concentrations and cortisol plasma 
levels. Furthermore, GLP-1 plasma concentrations significantly predicted endogenous insulin production as assessed 
by C-peptide concentrations over time, while an inverse association was found for insulin infusion rate.
Conclusion: We found GLP-1 secretion to be increased in response to inflammatory stimuli in humans, which was 
associated to parameters of glucose metabolism and best predicted by IL6.
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Background
Critical illness—as found during sepsis or acute myocar-
dial infarction—is a state of disarranged glucose metabo-
lism featuring episodes of hyper- and hypoglycemia [1]. 
States of hyperglycemia are attributable to the release 
of stress hormones including catecholamines, cortisol 
and glucagon leading to increased gluconeogenesis and 
inflammation mediated insulin resistance [2]. States of 
hypoglycemia, at the other end are the consequence of 
an activated, hypermetabolic immune system with aug-
mented glucose utilization, increased insulin secretion 
and inflammation induced suppression of gluconeogen-
esis [3, 4]. While hypoglycemic stimuli tend to dominate 
the early phase of acute inflammation, this is followed by 
a secondary increase of blood glucose with occurrence 
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of insulin resistance thereafter [5]. Early inflammation 
dependent insulin-secretion contributes to the initial 
drop of blood glucose values, which was recently found to 
be regulated by the incretin hormone glucagon-like pep-
tide-1 (GLP-1) [6]. GLP-1 is a gut-derived peptide, which 
stimulates glucose dependent insulin secretion from pan-
creatic beta-cells while also suppressing glucagon release 
from pancreatic alpha-cells [7]. GLP-1 secretion is clas-
sically induced by food ingestion and nutritional stimuli 
of the gut [7]. A similar induction of GLP-1 was recently 
found to occur in response to inflammatory stimuli 
including endotoxin and IL1 in mice [6]. These activate 
an inflammatory cascade leading to IL6 as a necessary 
and sufficient stimulus for inflammatory GLP-1 secre-
tion [6]. The translatability of these findings to humans is 
currently unknown but is suggested by marked elevation 
of circulating GLP-1 levels found in critical ill patients 
at time of admission to the intensive care unit (ICU) [6]. 
Furthermore, GLP-1 was found to be associated with 
inflammatory markers including IL6 in ICU patients with 
higher GLP-1 levels being present in septic than non-
septic patients [6]. Still, regulatory relevance of inflam-
mation for GLP-1 secretion remains largely unexplored 
in humans. This study aims to further characterize the 
regulation of GLP-1 secretion by inflammatory stimuli in 
humans. To do so, we have performed serial assessment 
of GLP-1 plasma levels in 22 patients undergoing car-
diac surgery with extracorporeal circulatory support as a 
defined and reproducible inflammatory stimulus.
Methods
We prospectively enrolled 22 non-diabetic patients (12 
male, 10 female) scheduled for cardiac surgery with car-
diopulmonary bypass and requirement of extracorporeal 
circulation [8]. Mean age was 66  years with an BMI of 
26.5 kg/m2. Patients were excluded from the study if they 
met the following criteria: pregnancy, diabetes mellitus, 
fasting glucose  >126  mg/dl, use of antidiabetic medica-
tion or glucocorticoids. Patients were fasting since the 
evening of the preoperative day. Blood samples were 
stored on ice and directly centrifuged. Blood glucose was 
assessed on an hourly basis and insulin-infusion rate con-
sequently adjusted to maintain glucose levels between 80 
and 126 mg/dl. Insulin and catecholamine infusion rates 
were recorded at the blood collection time points. No 
glucose containing solutions were given during the day of 
the procedure, while all patients were started on a con-
tinuous infusion of glucose 10 % with a rate of 10 ml/h 
at the morning of the first postoperative day. No addi-
tional parenteral or enteral nutrition was supplied during 
the observation period. The study protocol was approved 
by the Ethics Committee of the Ludwig-Maximilians-
University Munich, Germany. A control population of 
eight patients awaiting cardiac angiography was collected 
in the cardiology department of the university hospital 
Aachen with ethical approval gained by the Ethics Com-
mittee of the University Hospital Aachen. All patients 
gave informed written consent.
Laboratory procedures
Blood samples were stored at −70 °C until analysis. Total 
GLP-1 levels were determined as described previously 
using chemiluminescent enzyme-linked immunosorb-
ent assay (ELISA) [9]. Serum levels of TNFα, IL6, leptin, 
adiponectin and resistin were determined with a com-
mercial ELISA (R&D, Wiesbaden, Germany). Serum 
concentrations of cortisol, insulin, and C-peptide were 
quantified using a multichannel immunoanalyzer based 
on electrochemiluminescence as the principle of signal 
generation (Roche Cobas, Elecsys 2010; Roche Diagnos-
tics Mannheim, Germany) by the Department of Clinical 
Chemistry (Campus Grosshadern, University of Munich, 
Germany).
Statistical analysis
For description all continuous variables are expressed 
as mean values  ±  standard deviation (SD). Correla-
tions between baseline characteristics were assessed by 
the Spearman correlation coefficient which was simi-
larly performed at later time points. Depending on the 
presence of normally distributed data, paired t-tests 
and Wilcoxon signed rank sum tests were used to com-
pare the baseline concentration of parameters with later 
time points. Significant differences are presented in the 
boxplots (Fig.  1) and Additional file  1: Table S2. Two 
repeated measures ANCOVAs were performed: The 
first one to identify metabolic factors which show a sta-
tistical relationship to GLP-1 levels over time and the 
second one to evaluate the impact of GLP-1, gender, 
age, insulin-infusion rate and time of measurement on 
C-peptide. The response variables GLP-1 and C-peptide 
were logarithmized to meet the requirements for homo-
scedasticity and to acquire normally distributed data. A 
Kenward–Rogers adjustment was used to account for the 
small sample size. For the covariance a first order autore-
gressive structure was assumed in both analyses. For the 
univariable analysis of each metabolic factor a repeated 
measure analysis with the same assumptions was per-
formed in advance. For the GLP-1 response, the variable 
selection was performed as followed: Together with the 
clinical factors age, gender and time of measurement, all 
factors that were associated with GLP-1 in the univari-
able analyses with a P value  <0.20 were simultaneously 
analyzed in a multivariable model. Then, via backward 
selection, all factors were eliminated which impaired the 
model fit due to Akaike information criterion (AIC). All 
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factors with a P value  >0.20 in the univariable analyses 
were reconsidered by forward selection. Factors improv-
ing the AIC value were added to the model. All 2-way 
interactions were included in the model to explore pos-
sible effect modifiers. We assessed any effect in all tests 
as significant if the corresponding P value fell below 
the 5 % margin. All measurements of curves were fitted 
by locally weighted scatterplot smoothing, which uses 
weighted least squares to fit linear or quadratic func-
tions of the predictors at the centers of neighborhoods 
(Proc Loess). Boxplots were chosen to present the fluc-
tuations of selected factors over time. Statistical analysis 
was performed using SAS for Windows, Version 9.2 (SAS 
Institute, Cary, NC, USA), “Proc Mixed” was used for the 
repeated measure analysis.
Results
All patients (n  =  22) underwent open cardiac surgery 
with cardiopulmonary bypass. Patient characteristics are 
presented in Table 1. Blood samples were drawn directly 
before surgery (baseline), at arrival in the ICU (4–6  h 
time point), 6  h post arrival to the ICU (10–12  h time 
point) and the morning of the first and second postop-
erative days.
Mean total GLP-1 plasma concentrations did rise from 
25.5 ± 15.6 pM at baseline to 36.4 ± 28.7 pM after 4–6 h 
to reach a maximum of 51.9 ± 42.7 pM at 10–12 h after 
the beginning of surgery (P < 0.0001) (Fig. 1a). No change 
of GLP-1 plasma concentrations were detected in a con-
trol population (n  =  8) awaiting coronary angiography 
in the fasted state after 4 and 8 h (GLP-1 concentrations 
baseline: 25.4 ± 6.25 pM; after 4 h: 25.2 ± 8.37 pM; 8 h: 
26.0  ±  6.57  pM). Patient characteristics of the control 
population are presented in Additional file 1: Table S1.
In the surgical cohort, rise of GLP-1 was preceded 
by an early induction of the inflammatory cytokine IL6 
which peaked at the 4–6  h time point (Fig.  1b). Plasma 
glucose- (Fig.  1c) and C-peptide levels (Fig.  1d) were 
elevated at the early 4–6 h time point with a secondary 
decline thereafter, which was most likely attributable to 
exogenous insulin application (Fig. 1e) to maintain eugly-
cemia throughout the study period.
Spearman coefficient analysis was used to identify 
parameters associated with GLP-1 at different time 
points. While no relevant association was found at 
baseline, IL6 proved to be significantly associated with 
GLP-1 under inflammatory conditions at time points 2–4 
(Table 2 and Fig. 2). Furthermore, positive association of 
GLP-1 was detected with C-Peptide at a later time point 
and adrenalin-infusion at an early time point, while a 
negative association was recorded with leptin-levels at all 
time points after the beginning of surgery (Table 2).
To evaluate which parameter would best predict the 
rise of GLP-1 plasma concentrations over time, we per-
formed repeated measure ANCOVA under considera-
tion of age, sex, BMI and repetitive measurements of 
IL6, glucose, insulin, insulin-infusion rate, cortisol, lep-
tin, resistin, adiponectin, TNFα and adrenalin infusion 
rate (Additional file  1: Table S1). Using univariate anal-
ysis we found IL6 to best predict the kinetic of GLP-1 
over time (P  <  0.0001), which was followed by glucose 
(P  =  0.01) and insulin (P  =  0.04) (Table  3). This was 
GLP-1 over time IL6 over time
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Fig. 1 Kinetics of GLP-1 (a), IL6 (b), Glucose (c), C-Peptide (d) and 
Insulin-Infusion-Rate (e) over time with time point 1 illustrating blood 
drawn directly before surgery (baseline), time point 2: at arrival to the 
intensive care unit (4–6 h post initiation of surgery), time point 3: 6 h 
post arrival to the ICU (10–12 h post initiation of surgery) and the 
morning of the first (time point 4) and second (time point 5) post-
operative days. P-values indicate the comparison to baseline (time 
point 1) with * <0.05; ** <0.01; *** <0.001 using a paired t-tests and 
Wilcoxon signed rank sum tests for the differences





Body mass index (kg/m2) 26.12 (±3.55)
Hypertension 55
Smoker (yes) 32
Operation time (min) 278 (±60.13)
Heart/lung bypass time (min) 92 (±33.93)
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confirmed by multivariate analysis with IL6 providing 
the best predictor for the observed GLP-1 kinetic over 
time (P = 0.0009), followed by blood glucose concentra-
tions (P  =  0.03) and inversely by cortisol plasma levels 
(P = 0.03) (Table 4a).
To evaluate whether GLP-1 induction was second-
arily associated with insulin secretion we again per-
formed repeated measure ANCOVA using C-peptide as 
the dependent variable. Under further consideration of 
age, sex, repetitive measurement and insulin-infusion 
rate we found GLP-1 to significantly predict changes of 
C-peptide concentrations over time (P  =  0.007) while 
a negative trend was found for insulin-infusion rate 
(P = 0.0524) (Table 4b).
Discussion
In this study we used open heart surgery with extracor-
poreal circulatory support as a defined, reproducible 
stimulus to study inflammation dependent regulation of 
GLP-1 plasma levels in humans [8, 10, 11]. This demon-
strated a time dependent increase of circulating GLP-1 
levels, which recapitulates the inflammation dependent 
induction of GLP-1 in mice. Peak concentrations of GLP-1 
were found 10–12 h post-initiation of surgery, which was 
relatively delayed to endotoxin dependent peak GLP-1 
concentrations found 2  h after LPS application in mice 
[6]. This most likely reflects the differential inflammatory 
stimulus. In both species, GLP1 induction happened sec-
ondarily to an early rise of IL6, which is necessary and suf-
ficient for GLP-1 secretion in mice and also proved as the 
best predictor for GLP-1 kinetics in humans [6, 12]. This 
Table 2 Spearman-Coefficient of  GLP-1 with  different 
parameters for each time point
No insulin-infusion was present at baseline; time point 1: directly before surgery 
(baseline), time point 2: at arrival in the intensive care unit (4–6 h time point), 
time point 3: 6 h post arrival to the ICU (10–12 h time point), time point 4: 
morning of the first and time point 5: morning of the second postoperative day
Time-point 1 2 3 4 5
IL6 0.114 0.582 0.490 0.498 −0.058
P value 0.6150 0.0045 0.0207 0.0182 0.8260
Cortisol 0.427 0.199 −0.085 0.041 0.519
P value 0.0606 0.3743 0.7074 0.8550 0.0273
C-Peptide 0.360 0.179 0.406 0.440 −0.056
P value 0.1003 0.4252 0.0612 0.0404 0.8239
Insulin −0.276 0.147 −0.199 −0.163 0.078
P value 0.213 0.5146 0.3744 0.4698 0.7598
Glucose 0.115 0.039 0.168 −0.013 0.040
P value 0.6104 0.8632 0.4558 0.9541 0.8762
Leptin −0.299 −0.605 −0.543 −0.524 0.286
P value 0.1873 0.0037 0.0109 0.0147 0.2834
Resistin 0.218 0.134 0.187 0.166 0.424
P value 0.3418 0.5622 0.416 0.4716 0.1016
TNFa 0.169 0.088 −0.008 0.059 −0.252
P value 0.4632 0.7050 0.9732 0.7984 0.3640
Adiponectin −0.021 0.021 −0.282 −0.239 0.121
P value 0.9335 0.9293 0.2160 0.2964 0.6559
Adrenalin-Inf. −0.021 0.820 0.109 0.178 −0.197
P value 0.9356 <0.0001 0.6676 0.4793 0.4182
Insulin-Inf. – 0.100 0.064 −0.002 0.498
P value – 0.6594 0.7757 0.9931 0.0591
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Fig. 2 Fit-blot demonstrating the correlation of IL6 and log GLP-1 at 
arrival to the intensive care unit (time point 2)
Table 3 Univariate prediction of  GLP-1 plasma levels 
by different factors
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suggests a similar, species overlapping regulative mecha-
nism to be in place, which gets further supported by IL6 
dependent increase of GLP-1 secretion from human 
alpha-cells [12]. Mechanistically IL6 causes STAT-3 acti-
vation leading to proconvertase 1/3—the relevant GLP-1 
processing enzyme—and proglucagon expression [12]. 
On the contrary, GLP-1 administration has been found to 
reduce circulating IL6 concentrations in humans, which 
suggests the existence of a negative feedback loop as part 
of the anti-inflammatory capacities of GLP-1 [13]. Sur-
prisingly however, administration of TNFα, as an alter-
native inflammatory stimulus with strong IL6 inducing 
potential, failed to increase GLP-1 concentrations in mice 
and humans [6, 14]. This illustrates the complexity of a yet 
incompletely understood regulative mechanism of GLP-1 
secretion. We further found an early association of GLP-1 
with adrenalin infusion rate, which was not present at 
later time points, which recapitulates the GLP-1 induc-
ing capacity of adrenergic stimuli [15]. The mechanisms 
underlying the negative association of GLP-1 with leptin 
in this study remains to be explored and contrasts to the 
GLP-1 inducing capacity of leptin reported in the litera-
ture [16].
Interestingly, GLP-1 levels did predict endogenous 
insulin secretion as assessed by c-peptide kinetics in our 
study. This suggests functional relevance of inflammation 
induced GLP-1 secretion for insulin release in humans.
Therapies with GLP-1 receptor agonists have improved 
glucose control in critical ill patients. This proved effec-
tive in a small study population and lowered the need 
for exogenous insulin infusion with more stable glucose 
control and less hypoglycemic episodes [17, 18]. Given 
the high concentrations of endogenous GLP-1 found in 
critical ill patients, application of DPP-4 inhibitors might 
provide an alternative strategy to improve blood glucose 
control in this patient population.
Interestingly, GLP-1 receptor agonists and DPP-4 
inhibitors were found to similarly reduce mortality in 
inflammatory sepsis models [19]. This might relate to 
their capacity to reduce the inflammatory response, 
which has similarly been found in rodent models and 
humans [19–22]. Both substances also proved capable to 
ameliorate the chronic inflammatory process of rodent 
atherosclerosis [23, 24]. Whether these immune-modula-
tory capacities will translate to prognostic improvement 
of critical ill patients treated with GLP-1 modifying ther-
apies is currently unknown and remains to be explored.
This study has a variety of limitations. We are only 
able to present repeated associations of GLP-1 and other 
parameters in a longitudinal manner, which does not 
prove causality. Additional studies using IL6 modifying 
therapies will be required to prove the relevance of IL6 for 
inflammation induced GLP-1 secretion in humans. Appli-
cation of DPP-4 inhibitors and/or a GLP-1 receptor antag-
onist will help to elucidate the relevance of inflammatory 
GLP-1 secretion for glucose metabolism in humans.
In conclusion, we demonstrate GLP-1 secretion to be 
increased in response to open heart surgery with extra-
corporeal circulatory support as an inflammatory stimu-
lus in non-diabetic subjects, which was associated to 
factors of glucose metabolism and best explained by IL6.
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F value P value
a. GLP-1 plasma levels
 IL6 12.25 0.0009
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 TNFα 0.24 0.6266
b. C-peptide levels
 GLP-1 7.72 0.0071
 Time 5.79 0.0004
 Insulin-infusion 3.91 0.0524
 Gender 0.35 0.5613
 Age 0.02 0.8878
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